Company: LBRX
Filing Date: 2025-09-25
Form Type: SCHEDULE 13D
Source: 0001213900-25-091474
Chunk: 0

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-25
Form: SCHEDULE 13D
Chunk 0
---
 Based on 22,442,989 shares of Common Stock outstanding as of September 10, 2025, as provided for in LB Pharmaceuticals Inc.'s prospectus filed with the SEC on September 12, 2025.

| SCHEDULE 13D |

| CUSIP No. | 50180M108 |

| 1                                                                  |                                                                         Ran Nussbaum |
| 2                                                                  |                                                                                -a)(b |
| 3                                                                  |                                                                         SEC use only |
| 4                                                                  |                                                                                   AF |
| 5                                                                  |  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) |
| 6                                                                  |                                                                               ISRAEL |
| Number of Shares Beneficially Owned by Each Reporting Person With: |                                                                   7           0.00   
                                                                   8   1,411,681.00   
                                                                   9           0.00   
                                                                     10  1,411,681.00 |
| 11                                                                 |                                                                         1,411,681.00 |
| 12                                                                 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) |
| 13                                                                 |                                                                                6.3 % |
| 14                                                                 |                                                                                   IN |

Comment for Type of Reporting Person: 1. Includes (i) 898,201 Ordinary Shares held by Pontifax (Israel) VI Limited Partnership and (ii) 513,480 Ordinary Shares held by Pontifax (Cayman) VI Limited Partnership. Pontifax VI G.P. L.P. is the general partner of each of Pontifax (Israel) VI Limited Partnership and Pontifax (Cayman) VI Limited Partnership. Pontifax Management 4 G.P. (2015) Ltd. is the general partner of Pontifax VI G.P. L.P. Tomer Kariv and Ran Nussbaum are the Managing Partners of Pontifax Management 4 G.P. (2015) Ltd. and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax entities listed above. 2. Based on 22,442,989 shares of Common Stock outstanding as of September 10, 2025, as provided for in LB Pharmaceuticals Inc.'s prospectus filed with the SEC on September 12, 2025.

| SCHEDULE 13D |

| CUSIP No. | 50180M108 |

| 1